ASCO Direct Highlights Miami Symposium 2019 /
Recent advances in smouldering and relapsed or refractory multiple myeloma
ASCO Direct Highlights Miami Symposium 2019 /
Updates on hormone receptor-positive HER2-negative breast cancer
ASCO Direct Highlights Miami Symposium 2019 /
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials
Comment: POLO III trial for metastatic pancreatic cancer
ASCO 2019 /
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer
ASCO 2019 /
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer
ASCO 2019 /
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life
ASCO 2019 /
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer
ASCO 2019 /
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer
ASCO 2019 /
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment
ASCO 2019 /
Comment: The success of immunotherapy means we have to change our mindset as we treat patients
ASCO 2019 /
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer
ASCO 2019 /
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer
ASCO 2019 /
Breast cancer highlights from ASCO 2019
ASCO 2019 /
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC
TATTON: Updated results for patients with EGFR-mutant NSCLC
Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome
HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma
Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours
KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer
ASCO 2019 /
Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials
ASCO 2019 /
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases
ASCO 2019 /
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC
ASCO 2019 /
EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer
ASCO 2019 /
Ado-trastuzumab emansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial
ASCO Direct Highlights Miami Symposium 2019 /
Recent advances in smouldering and relapsed or refractory multiple myeloma ASCO Direct Highlights Miami Symposium 2019 /
Updates on hormone receptor-positive HER2-negative breast cancer ASCO Direct Highlights Miami Symposium 2019 /
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials Comment: POLO III trial for metastatic pancreatic cancer ASCO 2019 /
New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ASCO 2019 /
Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer ASCO 2019 /
Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life ASCO 2019 /
Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer ASCO 2019 /
Ribociclib and endocrine therapy improves survival for pre-menopausal women with advanced breast cancer ASCO 2019 /
Comment: The use of CDK 4/6 inhibitors now translates to a significant survival benefit in breast cancer treatment ASCO 2019 /
Comment: The success of immunotherapy means we have to change our mindset as we treat patients ASCO 2019 /
MONALEESA-7: Results from phase III trial looking at ribociclib as an addition to endocrine therapy in advanced breast cancer
ASCO 2019 /
POLO Trial: Olaparib as a maintenance treatment following first-line chemotherapy in patients with metastatic pancreatic cancer ASCO 2019 /
Breast cancer highlights from ASCO 2019 ASCO 2019 /
Biomarker analysis from JAVELIN Renal 101: Avelumab plus axitinib versus sunitinib in aRCC TATTON: Updated results for patients with EGFR-mutant NSCLC Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer ASCO 2019 /
Expanded clinical trial inclusion criteria would double the percentage of patients eligible to enrol in clinical trials
ASCO 2019 /
No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases
ASCO 2019 /
KEYNOTE-001: Five year data from the phase Ib trial studying pembrolizumab as treatment for aNSCLC
ASCO 2019 /
EMBRACA: Results of talazoparib vs chemotherapy relative to prior CT in patients with advanced breast cancer
ASCO 2019 /
Ado-trastuzumab emansine in patients with HER2 amplified salivary gland cancers: Results from a phase II basket trial
Important developments in radiation oncology
New standard of care for lung cancer patients with EGFR mutations
Evaluating treatment options for acute myeloid leukaemia
Updates on hormone receptor-positive HER2-negative breast cancer
Recent advances in smouldering and relapsed or refractory multiple myeloma
Latest updates in HER2-positive metastatic breast cancer: The NALA and SOPHIA trials
Lung cancer screening and the management of the pulmonary nodule
Immunotherapy for lung cancer before surgery
